Literature DB >> 36190530

Determinants of Low Bone Turnover in Type 2 Diabetes-the Role of PTH.

Janina Vavanikunnel1, Lilian Sewing1, Maria Triantafyllidou2, Anna Steighardt2, Sandra Baumann1, Andrea Egger1, Leticia Grize3,4, Barbara Felix5, Marius Kraenzlin6, Christoph Henzen2, Christian Meier7,8.   

Abstract

Determinants of low bone turnover in type 2 diabetes (T2DM) are poorly understood. To investigate the relationship between markers of bone turnover, glycaemic control, disease duration and calciotropic hormones in T2DM we assessed baseline biochemical data from the DiabOS Study, a prospective multicenter observational cohort study. In a cross-sectional study-design data from 110 postmenopausal women and men aged 50-75 years diagnosed with T2DM for at least 3 years and 92 non-diabetic controls were evaluated. Biochemical markers of bone formation (N-terminal propeptide of type I procollagen [PINP]), bone-specific alkaline phosphatase [BAP]) and resorption (C-terminal cross-linking telopeptide of type I collagen [CTX]), measures of calcium homeostasis (intact parathormone [iPTH], 25-Hydroxyvitamin D, calcium, magnesium) and glycaemic control were assessed. After adjustment for age, gender and body mass index (BMI), patients with T2DM had lower serum levels of PINP (p < 0.001), CTX (p < 0.001), iPTH (p = 0.03) and magnesium (p < 0.001) compared to controls. Serum calcium, creatinine, 25-Hydroxyvitamin D and sclerostin did not differ between both groups. In multivariate linear regression analyses only serum iPTH remained an independent determinant of bone turnover markers in T2DM (PINP: p = 0.02; CTX: p < 0.001 and BAP: p < 0.01), whereas glycated haemoglobin (HbA1c), disease duration, age and BMI were not associated with bone turnover. In conclusion low bone turnover in T2DM is associated with low iPTH. The underlying mechanism remains to be elucidated.
© 2022. The Author(s).

Entities:  

Keywords:  Bone turnover; Diabetes; Hypoparathyroidism

Year:  2022        PMID: 36190530     DOI: 10.1007/s00223-022-01022-7

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.000


  41 in total

Review 1.  Biochemical bone turnover markers in diabetes mellitus - A systematic review.

Authors:  Jakob Starup-Linde; Peter Vestergaard
Journal:  Bone       Date:  2015-02-24       Impact factor: 4.398

2.  In vivo assessment of bone quality in postmenopausal women with type 2 diabetes.

Authors:  Joshua N Farr; Matthew T Drake; Shreyasee Amin; L Joseph Melton; Louise K McCready; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

3.  Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk.

Authors:  Harald Dobnig; Jutta Claudia Piswanger-Sölkner; Martin Roth; Barbara Obermayer-Pietsch; Andreas Tiran; Andrea Strele; Elisabeth Maier; Peter Maritschnegg; Christian Sieberer; Astrid Fahrleitner-Pammer
Journal:  J Clin Endocrinol Metab       Date:  2006-05-30       Impact factor: 5.958

4.  Circulating osteogenic precursor cells in type 2 diabetes mellitus.

Authors:  J S Manavalan; S Cremers; D W Dempster; H Zhou; E Dworakowski; A Kode; S Kousteni; M R Rubin
Journal:  J Clin Endocrinol Metab       Date:  2012-06-27       Impact factor: 5.958

Review 5.  Biochemical markers of bone turnover in diabetes patients--a meta-analysis, and a methodological study on the effects of glucose on bone markers.

Authors:  J Starup-Linde; S A Eriksen; S Lykkeboe; A Handberg; P Vestergaard
Journal:  Osteoporos Int       Date:  2014-03-28       Impact factor: 4.507

6.  Bone structure and turnover in type 2 diabetes mellitus.

Authors:  A Shu; M T Yin; E Stein; S Cremers; E Dworakowski; R Ives; M R Rubin
Journal:  Osteoporos Int       Date:  2011-03-19       Impact factor: 4.507

7.  Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus.

Authors:  Ippei Kanazawa; Toru Yamaguchi; Masahiro Yamamoto; Mika Yamauchi; Soichi Kurioka; Shozo Yano; Toshitsugu Sugimoto
Journal:  J Clin Endocrinol Metab       Date:  2008-11-04       Impact factor: 5.958

8.  Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus.

Authors:  Masahiro Yamamoto; Mika Yamauchi; Toshitsugu Sugimoto
Journal:  J Clin Endocrinol Metab       Date:  2013-07-26       Impact factor: 5.958

9.  Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes.

Authors:  Mohammed-Salleh M Ardawi; Daad H Akhbar; Abdulrahman Alshaikh; Maimoona M Ahmed; Mohammed H Qari; Abdulrahim A Rouzi; Ahmed Y Ali; Adel A Abdulrafee; Mamdouh Y Saeda
Journal:  Bone       Date:  2013-07-09       Impact factor: 4.398

10.  Bone loss and bone turnover in diabetes.

Authors:  J C Krakauer; M J McKenna; N F Buderer; D S Rao; F W Whitehouse; A M Parfitt
Journal:  Diabetes       Date:  1995-07       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.